These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 39342325

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Diagnostic value of atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP) and their correlation with lipoproteins in dogs with myxomatous mitral valve disease.
    Khaki Z, Nooshirvani P, Shirani D, Masoudifard M.
    BMC Vet Res; 2022 Dec 23; 18(1):448. PubMed ID: 36564735
    [Abstract] [Full Text] [Related]

  • 24. Circulating cytokine concentrations in dogs with different degrees of myxomatous mitral valve disease.
    Zois NE, Moesgaard SG, Kjelgaard-Hansen M, Rasmussen CE, Falk T, Fossing C, Häggström J, Pedersen HD, Olsen LH.
    Vet J; 2012 Apr 23; 192(1):106-11. PubMed ID: 21696985
    [Abstract] [Full Text] [Related]

  • 25. Retrospective evaluation of the utility of shock index to determine the presence of congestive heart failure in dogs with myxomatous mitral valve disease (2019-2021): 98 cases.
    Matson H, Llewellyn EA.
    J Vet Emerg Crit Care (San Antonio); 2024 Apr 23; 34(3):231-237. PubMed ID: 38809224
    [Abstract] [Full Text] [Related]

  • 26. The prevalence of pulmonary hypertension in Cavalier King Charles spaniels compared with other breeds with myxomatous mitral valve disease.
    Sudunagunta S, Green D, Christley R, Dukes-McEwan J.
    J Vet Cardiol; 2019 Jun 23; 23():21-31. PubMed ID: 31174726
    [Abstract] [Full Text] [Related]

  • 27. Severity of myxomatous mitral valve disease in dogs may be predicted using neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratio.
    Ku D, Chae Y, Kim C, Koo Y, Lee D, Yun T, Chang D, Kang BT, Yang MP, Kim H.
    Am J Vet Res; 2023 Jun 01; 84(6):. PubMed ID: 37024099
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Dietary intervention reduces left atrial enlargement in dogs with early preclinical myxomatous mitral valve disease: a blinded randomized controlled study in 36 dogs.
    Li Q, Heaney A, Langenfeld-McCoy N, Boler BV, Laflamme DP.
    BMC Vet Res; 2019 Nov 27; 15(1):425. PubMed ID: 31775756
    [Abstract] [Full Text] [Related]

  • 30. Iron parameters analysis in dogs with myxomatous mitral valve disease.
    Kumiega E, A Kobak K, Noszczyk-Nowak A, Kasztura M.
    BMC Vet Res; 2024 May 18; 20(1):210. PubMed ID: 38762716
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The diagnostic relevance of NT-proBNP and proANP 31-67 measurements in staging of myxomatous mitral valve disease in dogs.
    Wolf J, Gerlach N, Weber K, Klima A, Wess G.
    Vet Clin Pathol; 2013 Jun 18; 42(2):196-206. PubMed ID: 23614733
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Predictors of reoccurrence of congestive signs within 180 days after successful treatment of the first episode of congestive heart failure in dogs with myxomatous mitral valve disease.
    Franchini A, Abbott JA, Tyrrell W, Rosenthal S, Lahmers S, Menciotti G, Crosara S, Häggström J, Borgarelli M.
    J Vet Cardiol; 2021 Apr 18; 34():112-119. PubMed ID: 33706221
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Brain-natriuretic peptide and cyclic guanosine monophosphate as biomarkers of myxomatous mitral valve disease in dogs.
    Moesgaard SG, Falk T, Teerlink T, Guðmundsdóttir HH, Sigurðardóttir S, Rasmussen CE, Olsen LH.
    Vet J; 2011 Sep 18; 189(3):349-52. PubMed ID: 20822939
    [Abstract] [Full Text] [Related]

  • 40. Metabolomics Analysis Reveals Deranged Energy Metabolism and Amino Acid Metabolic Reprogramming in Dogs With Myxomatous Mitral Valve Disease.
    Li Q, Larouche-Lebel É, Loughran KA, Huh TP, Suchodolski JS, Oyama MA.
    J Am Heart Assoc; 2021 May 04; 10(9):e018923. PubMed ID: 33890477
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.